Cargando…

Incidence and consequences of bone metastases in lung cancer patients

BACKGROUND: Bone metastases (BM) are common in NSCLC patients. Despite some potential positive effects of bone-targeted therapies, their use in NSCLC is infrequent, which may relate to the overall poor prognosis of advanced lung cancer. We reviewed the literature to evaluate the incidence, consequen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuchuk, Michael, Addison, Christina L., Clemons, Mark, Kuchuk, Iryna, Wheatley-Price, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723355/ https://www.ncbi.nlm.nih.gov/pubmed/26909268 http://dx.doi.org/10.1016/j.jbo.2012.12.004

Ejemplares similares

Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases
por: Simos, Demetrios, et al.
Publicado: (2013)

Incidence, consequences and treatment of bone metastases in breast cancer patients—Experience from a single cancer centre
por: Kuchuk, I., et al.
Publicado: (2013)

Oral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologists
por: Kuchuk, Iryna, et al.
Publicado: (2013)

Effects of de-escalated bisphosphonate therapy on the Functional Assessment of Cancer Therapy-Bone Pain, Brief Pain Inventory and bone biomarkers
por: Kuchuk, Iryna, et al.
Publicado: (2013)

Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient survey
por: Hutton, Brian, et al.
Publicado: (2013)

Does estrogen play a role in response to adjuvant bone-targeted therapies?
por: Russell, Kent, et al.
Publicado: (2013)

A national portfolio of bone oncology trials—The Canadian experience in 2012
por: Kuchuk, I., et al.
Publicado: (2012)

Evaluating the Feasibility of Performing Window of Opportunity Trials in Breast Cancer
por: Arnaout, Angel, et al.
Publicado: (2015)

Histomorphometric and microarchitectural analysis of bone in metastatic breast cancer patients
por: Beltran-Bless, A., et al.
Publicado: (2021)

A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer
por: Hutton, Brian, et al.
Publicado: (2013)

Histomorphometric and microarchitectural analyses using the 2 mm bone marrow trephine in metastatic breast cancer patients–preliminary results
por: Fralick, M., et al.
Publicado: (2012)

A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events
por: Addison, Christina L., et al.
Publicado: (2014)

Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases
por: Addison, Christina L, et al.
Publicado: (2014)

Accurate, explicit formulae for higher harmonic force spectroscopy by frequency modulation-AFM
por: Kuchuk, Kfir, et al.
Publicado: (2015)

Long-Term Potato Virus X (PVX)-Based Transient Expression of Recombinant GFP Protein in Nicotiana benthamiana Culture In Vitro
por: Sindarovska, Yana, et al.
Publicado: (2021)

Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer
por: Hilton, J.F., et al.
Publicado: (2017)

Doxycycline-Induced Changes in Circulating MMP or TIMP2 Levels Are Not Associated with Skeletal-Related Event-Free or Overall Survival in Patients with Bone Metastases from Breast Cancer
por: Zhao, Huijun, et al.
Publicado: (2023)

A primer of bone metastases management in breast cancer patients
por: Petrut, B., et al.
Publicado: (2008)

Bone-targeted therapy for metastatic breast cancer—Where do we go from here? A commentary from the BONUS 8 meeting
por: Zhu, Xiaofu, et al.
Publicado: (2014)

De-escalated administration of bone-targeted agents in patients with breast and prostate cancer—A survey of Canadian oncologists
por: Hutton, Brian, et al.
Publicado: (2013)

Bone metastases: Causes, consequences and therapeutic opportunities
por: Perez-Garcia, Jose, et al.
Publicado: (2013)

The Incidence of EGFR-Activating Mutations in Bone Metastases of Lung Adenocarcinoma
por: Krawczyk, Paweł, et al.
Publicado: (2013)

Increased ribonuclease activity in Solanum tuberosum L. transformed with heterologous genes of apoplastic ribonucleases as a putative approach for production of virus resistant plants
por: POTROKHOV, Andrii, et al.
Publicado: (2021)

The Growth of Polarization Domains in Ultrathin Ferroelectric Films Seeded by the Tip of an Atomic Force Microscope
por: Zamani-Alavijeh, Mohammad, et al.
Publicado: (2022)

Accumulation of colicin M protein and its biological activity in transgenic lettuce and mizuna plants
por: Shcherbak, Nataliia, et al.
Publicado: (2023)

Adjuvant bisphosphonate treatment for breast cancer: Where are we heading and can the pre-clinical literature help us get there?
por: Russell, Kent, et al.
Publicado: (2012)

Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study
por: Addison, Christina L., et al.
Publicado: (2015)

Detection of PIK3CA Mutations in Breast Cancer Bone Metastases
por: Daneshmand, Manijeh, et al.
Publicado: (2012)

{2,2′-[Ethane-1,2-diylbis(nitrilomethanylylidene)]diphenolato}(isopropanolato)aluminium dichloromethane hemisolvate
por: Zaitsev, Kirill V., et al.
Publicado: (2013)

Strategies for obtaining bone biopsy specimens from breast cancer patients – Past experience and future directions
por: Ibrahim, Mohammed F.K., et al.
Publicado: (2016)

Crystal structure of 4,8-di-tert-butyl-6,6-dichloro-13-ethyl-2,10-dimethyl-13,14-dihydro-12H-dibenzo[d,i][1,3,7,2]dioxazasilecine toluene 0.25-solvate
por: Kuchuk, Ekaterina A., et al.
Publicado: (2015)

Amniotic Membrane Biopolymer for Regenerative Medicine
por: Milyudin, Evgeny, et al.
Publicado: (2023)

Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey
por: Alzahrani, Mashari, et al.
Publicado: (2021)

Targeted Treatments of Bone Metastases in Patients with Lung Cancer
por: Hirsh, Vera
Publicado: (2014)

The risk factors of bone metastases in patients with lung cancer
por: Zhou, Yang, et al.
Publicado: (2017)

Brief Report: Medical Assistance in Dying in Patients With Lung Cancer
por: Moore, Sara, et al.
Publicado: (2022)

Robust Agrobacterium-Mediated Transient Expression in Two Duckweed Species (Lemnaceae) Directed by Non-replicating, Replicating, and Cell-to-Cell Spreading Vectors
por: Peterson, Anton, et al.
Publicado: (2021)

National Suicide Prevention Lifeline crisis chat interventions: Evaluation of chatters’ perceptions of effectiveness
por: Gould, Madelyn S., et al.
Publicado: (2021)

Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey
por: AlZahrani, Mashari, et al.
Publicado: (2020)

Incidence proportions and prognosis of breast cancer patients with bone metastases at initial diagnosis
por: Gong, Yue, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gfttkcplv2gmtg72l77me6m6ni